Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators
Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%–95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially...
Saved in:
| Published in | Drug metabolism and disposition Vol. 48; no. 3; pp. 230 - 244 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.03.2020
American Society for Pharmacology and Experimental Therapeutics, Inc The American Society for Pharmacology and Experimental Therapeutics |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%–95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially ester-prodrugs), pesticides, environmental pollutants, and endogenous compounds. Expression and activity of CES1 vary markedly among individuals, which is a major contributing factor to interindividual variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by CES1. Both genetic and nongenetic factors contribute to CES1 variability. Here, we discuss genetic polymorphisms, including single-nucleotide polymorphisms (SNPs), and copy number variants and nongenetic contributors, such as developmental status, genders, and drug-drug interactions, that could influence CES1 functionality and the PK and PD of CES1 substrates. Currently, the loss-of-function SNP G143E (rs71647871) is the only clinically significant CES1 variant identified to date, and alcohol is the only potent CES1 inhibitor that could alter the therapeutic outcomes of CES1 substrate medications. However, G143E and alcohol can only explain a small portion of the interindividual variability in the CES1 function. A better understanding of the regulation of CES1 expression and activity and identification of biomarkers for CES1 function in vivo could lead to the development of a precision pharmacotherapy strategy to improve the efficacy and safety of many CES1 substrate drugs.
The clinical relevance of CES1 has been well demonstrated in various clinical trials. Genetic and nongenetic regulators can affect CES1 expression and activity, resulting in the alteration of the metabolism and clinical outcome of CES1 substrate drugs, such as methylphenidate and clopidogrel. Predicting the hepatic CES1 function can provide clinical guidance to optimize pharmacotherapy of numerous medications metabolized by CES1. |
|---|---|
| AbstractList | Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%–95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially ester-prodrugs), pesticides, environmental pollutants, and endogenous compounds. Expression and activity of CES1 vary markedly among individuals, which is a major contributing factor to interindividual variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by CES1. Both genetic and nongenetic factors contribute to CES1 variability. Here, we discuss genetic polymorphisms, including single-nucleotide polymorphisms (SNPs), and copy number variants and nongenetic contributors, such as developmental status, genders, and drug-drug interactions, that could influence CES1 functionality and the PK and PD of CES1 substrates. Currently, the loss-of-function SNP G143E (rs71647871) is the only clinically significant
CES1
variant identified to date, and alcohol is the only potent CES1 inhibitor that could alter the therapeutic outcomes of CES1 substrate medications. However, G143E and alcohol can only explain a small portion of the interindividual variability in the CES1 function. A better understanding of the regulation of CES1 expression and activity and identification of biomarkers for CES1 function in vivo could lead to the development of a precision pharmacotherapy strategy to improve the efficacy and safety of many CES1 substrate drugs. Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%–95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially ester-prodrugs), pesticides, environmental pollutants, and endogenous compounds. Expression and activity of CES1 vary markedly among individuals, which is a major contributing factor to interindividual variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by CES1. Both genetic and nongenetic factors contribute to CES1 variability. Here, we discuss genetic polymorphisms, including single-nucleotide polymorphisms (SNPs), and copy number variants and nongenetic contributors, such as developmental status, genders, and drug-drug interactions, that could influence CES1 functionality and the PK and PD of CES1 substrates. Currently, the loss-of-function SNP G143E (rs71647871) is the only clinically significant CES1 variant identified to date, and alcohol is the only potent CES1 inhibitor that could alter the therapeutic outcomes of CES1 substrate medications. However, G143E and alcohol can only explain a small portion of the interindividual variability in the CES1 function. A better understanding of the regulation of CES1 expression and activity and identification of biomarkers for CES1 function in vivo could lead to the development of a precision pharmacotherapy strategy to improve the efficacy and safety of many CES1 substrate drugs. Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%–95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially ester-prodrugs), pesticides, environmental pollutants, and endogenous compounds. Expression and activity of CES1 vary markedly among individuals, which is a major contributing factor to interindividual variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by CES1. Both genetic and nongenetic factors contribute to CES1 variability. Here, we discuss genetic polymorphisms, including single-nucleotide polymorphisms (SNPs), and copy number variants and nongenetic contributors, such as developmental status, genders, and drug-drug interactions, that could influence CES1 functionality and the PK and PD of CES1 substrates. Currently, the loss-of-function SNP G143E (rs71647871) is the only clinically significant CES1 variant identified to date, and alcohol is the only potent CES1 inhibitor that could alter the therapeutic outcomes of CES1 substrate medications. However, G143E and alcohol can only explain a small portion of the interindividual variability in the CES1 function. A better understanding of the regulation of CES1 expression and activity and identification of biomarkers for CES1 function in vivo could lead to the development of a precision pharmacotherapy strategy to improve the efficacy and safety of many CES1 substrate drugs. The clinical relevance of CES1 has been well demonstrated in various clinical trials. Genetic and nongenetic regulators can affect CES1 expression and activity, resulting in the alteration of the metabolism and clinical outcome of CES1 substrate drugs, such as methylphenidate and clopidogrel. Predicting the hepatic CES1 function can provide clinical guidance to optimize pharmacotherapy of numerous medications metabolized by CES1. Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%-95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially ester-prodrugs), pesticides, environmental pollutants, and endogenous compounds. Expression and activity of CES1 vary markedly among individuals, which is a major contributing factor to interindividual variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by CES1. Both genetic and nongenetic factors contribute to CES1 variability. Here, we discuss genetic polymorphisms, including single-nucleotide polymorphisms (SNPs), and copy number variants and nongenetic contributors, such as developmental status, genders, and drug-drug interactions, that could influence CES1 functionality and the PK and PD of CES1 substrates. Currently, the loss-of-function SNP G143E (rs71647871) is the only clinically significant CES1 variant identified to date, and alcohol is the only potent CES1 inhibitor that could alter the therapeutic outcomes of CES1 substrate medications. However, G143E and alcohol can only explain a small portion of the interindividual variability in the CES1 function. A better understanding of the regulation of CES1 expression and activity and identification of biomarkers for CES1 function in vivo could lead to the development of a precision pharmacotherapy strategy to improve the efficacy and safety of many CES1 substrate drugs. SIGNIFICANCE STATEMENT: The clinical relevance of CES1 has been well demonstrated in various clinical trials. Genetic and nongenetic regulators can affect CES1 expression and activity, resulting in the alteration of the metabolism and clinical outcome of CES1 substrate drugs, such as methylphenidate and clopidogrel. Predicting the hepatic CES1 function can provide clinical guidance to optimize pharmacotherapy of numerous medications metabolized by CES1.Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%-95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially ester-prodrugs), pesticides, environmental pollutants, and endogenous compounds. Expression and activity of CES1 vary markedly among individuals, which is a major contributing factor to interindividual variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by CES1. Both genetic and nongenetic factors contribute to CES1 variability. Here, we discuss genetic polymorphisms, including single-nucleotide polymorphisms (SNPs), and copy number variants and nongenetic contributors, such as developmental status, genders, and drug-drug interactions, that could influence CES1 functionality and the PK and PD of CES1 substrates. Currently, the loss-of-function SNP G143E (rs71647871) is the only clinically significant CES1 variant identified to date, and alcohol is the only potent CES1 inhibitor that could alter the therapeutic outcomes of CES1 substrate medications. However, G143E and alcohol can only explain a small portion of the interindividual variability in the CES1 function. A better understanding of the regulation of CES1 expression and activity and identification of biomarkers for CES1 function in vivo could lead to the development of a precision pharmacotherapy strategy to improve the efficacy and safety of many CES1 substrate drugs. SIGNIFICANCE STATEMENT: The clinical relevance of CES1 has been well demonstrated in various clinical trials. Genetic and nongenetic regulators can affect CES1 expression and activity, resulting in the alteration of the metabolism and clinical outcome of CES1 substrate drugs, such as methylphenidate and clopidogrel. Predicting the hepatic CES1 function can provide clinical guidance to optimize pharmacotherapy of numerous medications metabolized by CES1. Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is responsible for 80%-95% of total hydrolytic activity in the liver and plays a crucial role in the metabolism of a wide range of drugs (especially ester-prodrugs), pesticides, environmental pollutants, and endogenous compounds. Expression and activity of CES1 vary markedly among individuals, which is a major contributing factor to interindividual variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by CES1. Both genetic and nongenetic factors contribute to CES1 variability. Here, we discuss genetic polymorphisms, including single-nucleotide polymorphisms (SNPs), and copy number variants and nongenetic contributors, such as developmental status, genders, and drug-drug interactions, that could influence CES1 functionality and the PK and PD of CES1 substrates. Currently, the loss-of-function SNP G143E (rs71647871) is the only clinically significant variant identified to date, and alcohol is the only potent CES1 inhibitor that could alter the therapeutic outcomes of CES1 substrate medications. However, G143E and alcohol can only explain a small portion of the interindividual variability in the CES1 function. A better understanding of the regulation of CES1 expression and activity and identification of biomarkers for CES1 function in vivo could lead to the development of a precision pharmacotherapy strategy to improve the efficacy and safety of many CES1 substrate drugs. SIGNIFICANCE STATEMENT: The clinical relevance of CES1 has been well demonstrated in various clinical trials. Genetic and nongenetic regulators can affect CES1 expression and activity, resulting in the alteration of the metabolism and clinical outcome of CES1 substrate drugs, such as methylphenidate and clopidogrel. Predicting the hepatic CES1 function can provide clinical guidance to optimize pharmacotherapy of numerous medications metabolized by CES1. |
| Author | Her, Lucy Zhu, Hao-Jie |
| Author_xml | – sequence: 1 givenname: Lucy orcidid: 0000-0003-0340-2323 surname: Her fullname: Her, Lucy – sequence: 2 givenname: Hao-Jie surname: Zhu fullname: Zhu, Hao-Jie |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31871135$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UUFrFDEUDlKx2-rVowx48TJrMplMEg-CLFqFokUUPAghk7zZTZlJ1iRT3H_f1F0XLfT0XvK-7-O97ztDJz54QOg5wUtCmva1nWxp5BIL2Qn8CC0Ia0iNsfxxghal4Foy1p2is5SuMSZtS-UTdEqJ4IRQtkA_Vzr24fduhJQh6gQVqbS31VUE45ILvrra6DhpE_KmzLe7N8ePNXjIzqQ_-M_BH97VV1jPo84hpqfo8aDHBM8O9Rx9__D-2-pjffnl4tPq3WVtGKW5biRwbSUHOTRgxdANum-7vu0HkNK0rLG4Z4RREFb0A-d8oNwQbKyQhrfS0nP0dq-7nfsJrAGfox7VNrpJx50K2qn_J95t1DrcKI4p4V1XBF4dBGL4NRcr1OSSgXHUHsKcVEMppo1gkhXoy3vQ6zBHX84rKM5EQ7i8E3zx70bHVf4aXwDLPcDEkFKE4QghWN0lq0qypZFqn2whtPcIxmWdS0LlIjc-TBN7GhT_bxxElYwDb8C6knBWNriHqLdSQryY |
| CitedBy_id | crossref_primary_10_1016_j_tiv_2024_105833 crossref_primary_10_1007_s13353_024_00831_w crossref_primary_10_1007_s44254_025_00090_w crossref_primary_10_1016_j_envres_2023_116413 crossref_primary_10_1111_cts_70079 crossref_primary_10_1038_s41598_020_78231_3 crossref_primary_10_1016_j_biopha_2024_116720 crossref_primary_10_1002_pmic_202200176 crossref_primary_10_1039_D0FO01732A crossref_primary_10_1016_j_cbi_2021_109744 crossref_primary_10_1021_acs_molpharmaceut_3c01089 crossref_primary_10_1016_j_bcp_2022_115250 crossref_primary_10_1124_dmd_120_000323 crossref_primary_10_1016_j_cbi_2022_110228 crossref_primary_10_1155_2023_5935657 crossref_primary_10_3389_fphar_2024_1434137 crossref_primary_10_1016_j_apsb_2022_10_017 crossref_primary_10_1007_s00228_023_03484_6 crossref_primary_10_1038_s43856_023_00338_1 crossref_primary_10_1002_cpt_2486 crossref_primary_10_2174_0113892002300657240521094732 crossref_primary_10_1111_bcp_15981 crossref_primary_10_1016_j_neubiorev_2021_11_019 crossref_primary_10_1002_pro_5098 crossref_primary_10_1016_j_ejmech_2021_113385 crossref_primary_10_1124_dmd_123_001345 crossref_primary_10_3389_fnut_2022_935112 crossref_primary_10_1016_j_chest_2024_01_014 crossref_primary_10_1186_s12906_024_04573_4 crossref_primary_10_1021_acs_jproteome_3c00496 crossref_primary_10_1016_j_cbi_2023_110612 crossref_primary_10_1016_j_jpba_2023_115639 crossref_primary_10_3390_molecules27185922 crossref_primary_10_1111_cts_12989 crossref_primary_10_1124_dmd_124_001916 crossref_primary_10_1097_JCP_0000000000001772 crossref_primary_10_1016_j_cbi_2022_110197 crossref_primary_10_1016_j_ejmech_2023_115513 crossref_primary_10_3390_pharmaceutics16020234 crossref_primary_10_1039_D3TB02759G crossref_primary_10_1039_D4CC03632H crossref_primary_10_1111_bcp_14888 crossref_primary_10_1039_D2CS00673A crossref_primary_10_1016_j_biopha_2023_114956 crossref_primary_10_1016_j_bcp_2024_116128 crossref_primary_10_1124_dmd_120_000065 crossref_primary_10_1080_17425255_2024_2348491 crossref_primary_10_1016_j_xphs_2022_04_019 crossref_primary_10_3390_genes13122225 crossref_primary_10_1093_jleuko_qiae137 crossref_primary_10_3390_jpm11121262 crossref_primary_10_1002_cbic_202200069 crossref_primary_10_1016_j_lfs_2022_120790 crossref_primary_10_1039_D1MD00073J crossref_primary_10_1007_s00204_022_03332_z crossref_primary_10_1007_s00280_020_04087_z crossref_primary_10_1124_dmd_123_001487 crossref_primary_10_1016_j_eng_2021_09_014 crossref_primary_10_1111_bcpt_13707 crossref_primary_10_1039_D2CC04237A crossref_primary_10_2217_pgs_2021_0108 crossref_primary_10_1093_ehjcvp_pvae064 crossref_primary_10_1124_dmd_121_000823 crossref_primary_10_1371_journal_pone_0278111 crossref_primary_10_1016_j_dmd_2025_100049 crossref_primary_10_1021_acs_molpharmaceut_4c00542 crossref_primary_10_1038_s41598_023_37150_9 crossref_primary_10_1016_j_cbi_2022_110097 crossref_primary_10_1039_D4NJ00486H crossref_primary_10_3389_fped_2022_958622 crossref_primary_10_1016_j_chc_2022_03_003 |
| Cites_doi | 10.1124/dmd.113.054353 10.1111/j.1365-2125.2010.03695.x 10.1016/j.cbi.2006.07.001 10.1016/j.bbalip.2018.04.002 10.1016/j.bbalip.2009.09.002 10.1200/JCO.2004.07.173 10.1124/dmd.117.077669 10.1038/nrd2468 10.1007/s00228-016-2029-x 10.2174/1570161113666150916094829 10.1002/cpt.101 10.1124/dmd.106.009381 10.1124/dmd.115.068536 10.1007/s11095-011-0637-9 10.1089/cap.2013.0032 10.1007/s00228-012-1315-5 10.1124/dmd.116.072652 10.1007/s00213-012-2849-z 10.1208/s12248-014-9620-9 10.1584/jpestics.R10-07 10.1097/JCP.0000000000000721 10.1124/jpet.112.201640 10.1016/j.vph.2009.10.002 10.1007/s13238-017-0437-z 10.1056/NEJMoa0904327 10.1038/tpj.2015.42 10.2165/00044011-200323090-00002 10.1002/cpt.641 10.1002/jps.22476 10.1038/sj.clpt.6100082 10.1016/j.ajhg.2008.04.015 10.1038/tpj.2010.5 10.3390/molecules24152747 10.1016/j.ejps.2015.10.024 10.1371/journal.pone.0143919 10.1097/01.fpc.0000230110.18957.50 10.2165/00023210-200620090-00002 10.1016/j.bcp.2008.10.005 10.1016/j.pbb.2011.08.026 10.2133/dmpk.23.73 10.1111/bcp.12682 10.1016/j.pbb.2010.01.009 10.1161/CIRCULATIONAHA.112.001233 10.1001/jama.288.19.2411 10.1002/rcm.7482 10.1097/FPC.0b013e32830b0c5e 10.1016/j.neuropharm.2009.08.014 10.1517/17425250903483215 10.1097/FPC.0000000000000203 10.1124/dmd.116.071753 10.1038/clpt.2014.183 10.1038/tpj.2012.25 10.1016/j.bbrc.2008.02.120 10.1016/j.jprot.2019.03.005 10.1056/NEJMoa1205512 10.1056/NEJMoa0706482 10.1016/j.bcp.2008.12.017 10.1371/journal.pone.0176320 10.1124/dmd.115.068957 10.1161/CIR.0000000000000509 10.1038/npp.2017.198 10.1097/FJC.0000000000000037 10.1007/s00228-016-2094-1 10.1007/s40262-014-0226-2 10.1002/psp4.12309 10.1111/bcpt.12835 10.1007/s00018-004-3426-3 10.1111/bcpt.12625 10.1111/bcp.12667 10.1016/j.bcp.2012.04.002 10.1124/dmd.112.048397 10.1152/ajpcell.00306.2006 10.1124/dmd.108.024943 10.1093/infdis/jiq145 10.1007/s00228-012-1352-0 10.1124/dmd.111.042259 10.1097/FPC.0000000000000035 10.1124/dmd.118.086074 10.1007/s11096-015-0159-3 10.1111/irv.12552 10.1291/hypres.28.719 10.1124/dmd.113.053512 10.1124/jpet.106.111807 10.2133/dmpk.DMPK-12-RV-042 10.1016/j.tox.2008.09.019 10.1124/dmd.112.048595 10.1038/s41598-017-07736-1 10.1002/phar.1194 10.1371/journal.pone.0056861 10.1038/clpt.2013.105 10.1038/clpt.2012.13 10.1016/j.jchromb.2011.02.033 10.1016/j.bcp.2007.06.022 10.1124/dmd.109.028209 10.1097/FPC.0b013e32835aa8a2 10.1007/s40262-014-0160-3 10.1016/S0140-6736(01)05701-4 10.2174/187231211798472511 10.1016/j.bcp.2016.09.003 10.1371/journal.pone.0109663 10.1016/j.ejps.2017.08.002 10.1016/j.tox.2010.01.009 10.1111/bcp.13237 |
| ContentType | Journal Article |
| Copyright | 2019 American Society for Pharmacology and Experimental Therapeutics Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics. Copyright Lippincott Williams & Wilkins Ovid Technologies Mar 1, 2020 Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics 2020 |
| Copyright_xml | – notice: 2019 American Society for Pharmacology and Experimental Therapeutics – notice: Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics. – notice: Copyright Lippincott Williams & Wilkins Ovid Technologies Mar 1, 2020 – notice: Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7TK 7U7 8FD C1K FR3 P64 7X8 5PM |
| DOI | 10.1124/dmd.119.089680 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Biotechnology Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Carboxylesterase 1 and Precision Pharmacotherapy |
| EISSN | 1521-009X |
| EndPage | 244 |
| ExternalDocumentID | PMC7031766 31871135 10_1124_dmd_119_089680 S0090955624080693 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL126969 |
| GroupedDBID | --- .GJ 0R~ 18M 2WC 4.4 53G 5GY 5RE 5VS AAXUO ABJNI ABSQV ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AERNN AFFNX AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC KQ8 LSO M41 O9- OK1 P2P R0Z RHI ROL RPT SJN TR2 VH1 W8F WH7 WOQ YCJ YHG ZGI ZXP ~KM AALRI AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7TK 7U7 8FD C1K FR3 P64 7X8 5PM |
| ID | FETCH-LOGICAL-c533t-29e7ad97e9f2ed8f6fab46b4bfe99c452d0b5153e8d8bf777f37c10cd89c749d3 |
| ISSN | 0090-9556 1521-009X |
| IngestDate | Thu Aug 21 18:03:52 EDT 2025 Fri Jul 11 01:48:52 EDT 2025 Mon Jun 30 12:06:43 EDT 2025 Mon Jul 21 05:43:53 EDT 2025 Tue Jul 01 05:28:27 EDT 2025 Thu Apr 24 23:03:56 EDT 2025 Sun Apr 06 06:53:02 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | ADHD FDA CBD M1 M2 CNV PNPA ADP CBN THC AUC PAPI SNP ACEI CYP ID DME DABE AA LOF CI CES AT BCS MAF PD PK VASP-PRI UGT1A |
| Language | English |
| License | Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c533t-29e7ad97e9f2ed8f6fab46b4bfe99c452d0b5153e8d8bf777f37c10cd89c749d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-0340-2323 |
| OpenAccessLink | https://dmd.aspetjournals.org/content/dmd/48/3/230.full.pdf |
| PMID | 31871135 |
| PQID | 2375821796 |
| PQPubID | 2048316 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7031766 proquest_miscellaneous_2330328595 proquest_journals_2375821796 pubmed_primary_31871135 crossref_primary_10_1124_dmd_119_089680 crossref_citationtrail_10_1124_dmd_119_089680 elsevier_sciencedirect_doi_10_1124_dmd_119_089680 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | March 2020 2020-03-00 20200301 |
| PublicationDateYYYYMMDD | 2020-03-01 |
| PublicationDate_xml | – month: 03 year: 2020 text: March 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Bethesda – name: Bethesda, MD |
| PublicationTitle | Drug metabolism and disposition |
| PublicationTitleAlternate | Drug Metab Dispos |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc American Society for Pharmacology and Experimental Therapeutics, Inc The American Society for Pharmacology and Experimental Therapeutics |
| Publisher_xml | – name: Elsevier Inc – name: American Society for Pharmacology and Experimental Therapeutics, Inc – name: The American Society for Pharmacology and Experimental Therapeutics |
| References | Kaddurah-Daouk, Hankemeier, Scholl, Baillie, Harms, Stage, Dalhoff, Jűrgens, Taboureau, Nzabonimpa (bib38) 2018; 7 Tarkiainen, Holmberg, Tornio, Neuvonen, Neuvonen, Backman, Niemi (bib82) 2015; 97 Zhu, Appel, Peterson, Wang, Markowitz (bib103) 2010; 270 Bruxel, Salatino-Oliveira, Genro, Zeni, Polanczyk, Chazan, Rohde, Hutz (bib8) 2013; 13 Cressman, Macdonald, Fernandes, Gomes, Paterson, Mamdani, Juurlink (bib11) 2015; 80 Rhoades, Peterson, Zhu, Appel, Peloquin, Markowitz (bib58) 2012; 29 Wallentin, Becker, Budaj, Cannon, Emanuelsson, Held, Horrow, Husted, James, Katus (bib85) 2009; 361 Patrick, Straughn, Minhinnett, Yeatts, Herrin, DeVane, Malcolm, Janis, Markowitz (bib53) 2007; 81 Schubert, Köster, Lehmkuhl (bib63) 2010; 107 Lian, Bahitham, Panigrahi, Nelson, Li, Watts, Thiesen, Lemieux, Lehner (bib43) 2018; 1863 Shah, Amidon (bib65) 2014; 16 Stage, Jürgens, Guski, Thomsen, Bjerre, Ferrero-Miliani, Lyauk, Rasmussen, Dalhoff (bib74) 2017; 83 Zhu, Wang, Gawronski, Brinda, Angiolillo, Markowitz (bib109) 2013; 344 Shi, Yang, Yang, Yan (bib68) 2008; 254 Laizure, Parker, Herring, Hu (bib41) 2014; 42 He, Shi, Wang, Jiang, Zhu (bib27) 2019; 200 Shmyr, Van der Merwe, Yakiwchuk, Barry, Kosar (bib72) 2017; 63 Zhu, Patrick, Straughn, Reeves, Bernstein, Shi, Johnson, Knight, Smith, Malcolm (bib107) 2017; 37 Steinhubl, Berger, Mann, Fry, DeLago, Wilmer, Topol (bib77) 2002; 288 Shi, Yang, Prinssen, Davies, Yan (bib66) 2011; 203 COTEMPLA XR-ODT(TM) (2017) Product Information: COTEMPLA XR-ODT(TM) oral extended-release disintegrating tablets, methylphenidate oral extended-release disintegrating tablets. Neos Therapeutics IGP, Grand Prairie, TX. Crow, Herring, Xie, Borazjani, Potter, Ross (bib12) 2010; 1801 Dahlgren, Shay, Izurieta, Forshee, Wernecke, Chillarige, Lu, Kelman, Reed (bib13) 2018; 12 Wang, Liang, Liu, Shi, Zhu (bib86) 2016; 30 Wang, Rida, Shi, Wu, Bleske, Zhu (bib87) 2017; 45 Hines, Simpson, McCarver (bib29) 2016; 44 Tarkiainen, Tornio, Holmberg, Launiainen, Neuvonen, Backman, Niemi (bib83) 2015; 80 Bell, Griffin, Patrick (bib3) 2011; 100 Briand, Thomsen, Linnet, Rasmussen, Brunak, Taboureau (bib7) 2019; 24 Hasin (bib26) 2018; 43 Singh, Barghoorn, Bagdonas, Adler, Treanor, Kinnersley, Ward (bib73) 2003; 23 Jewell, Bennett, Mutch, Ackermann, Williams (bib34) 2007; 74 Xie, Ding, Gao, Wang, Hang, Zhang, Zhang, Jiang, Miao (bib93) 2014; 24 Mehta, Yusuf, Peters, Bertrand, Lewis, Natarajan, Malmberg, Rupprecht, Zhao, Chrolavicius (bib46) 2001; 358 Zhu, Appel, Jiang, Markowitz (bib101) 2009; 37 Hamzic, Kummer, Milesi, Mueller, Joerger, Aebi, Amstutz, Largiader (bib25) 2017; 102 Geshi, Kimura, Yoshimura, Suzuki, Koba, Sakai, Saito, Koga, Muramatsu, Katagiri (bib21) 2005; 28 Kristensen, Zhu, Wang, Gislason, Torp-Pedersen, Rasmussen, Markowitz, Hansen (bib39) 2014; 96 Scott, Sangkuhl, Stein, Hulot, Mega, Roden, Klein, Sabatine, Johnson, Shuldiner (bib64) 2013; 94 Oh, Lee, Lee, Cho, Yoon, Jang, Yu, Lim (bib49) 2017; 12 Roe, Armstrong, Fox, White, Prabhakaran, Goodman, Cornel, Bhatt, Clemmensen, Martinez (bib59) 2012; 367 Nelveg-Kristensen, Madsen, Torp-Pedersen, Køber, Egfjord, Hansen, Pedersen, Rasmussen, Hansen (bib47) 2016; 26 Staudinger, Xu, Cui, Klaassen (bib76) 2010; 6 Zhu, Patrick, Yuan, Wang, Donovan, DeVane, Malcolm, Johnson, Youngblood, Sweet (bib108) 2008; 82 DiPiro (bib14) 2017 Imai, Taketani, Shii, Hosokawa, Chiba (bib32) 2006; 34 Satoh, Hosokawa (bib62) 2006; 162 Ohtsuki, Schaefer, Kawakami, Inoue, Liehner, Saito, Ishiguro, Kishimoto, Ludwig-Schwellinger, Ebner (bib50) 2012; 40 Zhu, Langaee, Gong, Wang, Pepine, Cooper-DeHoff, Johnson, Markowitz (bib104) 2016; 72 Dolinsky, Gilham, Alam, Vance, Lehner (bib15) 2004; 61 Bozzi, Mitchell, Lewis, Ryan, Herzog, O’Connell, Horenstein, Shuldiner, Yerges-Armstrong (bib6) 2016; 14 Griffin, McGovern, Bell, Randall, Middaugh, Patrick (bib23) 2013; 225 Chaturvedi (bib9) 2004; 17 Lian, Nelson, Lehner (bib44) 2018; 9 Jones, Taylor, Tong, Repa (bib37) 2013; 41 Suzaki, Uemura, Hosokawa, Ohashi (bib78) 2013; 69 Zhu, Patrick, Markowitz (bib106) 2011; 879 Parker, Hu, Meibohm, Laizure (bib52) 2015; 54 Foye, Lemke, Williams (bib17) 2013 Bell, Novak, Griffin, Patrick (bib4) 2011; 100 Suzaki, Uemura, Takada, Ohyama, Itohda, Morimoto, Imai, Hamasaki, Inano, Hosokawa (bib79) 2013; 69 Rautio, Kärkkäinen, Sloan (bib56) 2017; 109 Griffin, Novak, Middaugh, Patrick (bib24) 2010; 95 Shi, Wang, Eyler, Liang, Liu, Mueller, Zhu (bib69) 2016; 119 Ross, Streit, Herring (bib60) 2010; 35 Yoshimura, Kimura, Ishii, Ishii, Matsuura, Geshi, Hosokawa, Muramatsu (bib98) 2008; 369 Thomsen, Rasmussen, Linnet (bib84) 2014; 42 Jiang, Samant, Lewis, Horenstein, Shuldiner, Yerges-Armstrong, Peletier, Lesko, Schmidt (bib35) 2016; 82 Lewis, Horenstein, Ryan, O’Connell, Gibson, Mitchell, Tanner, Chai, Bliden, Tantry (bib42) 2013; 23 Hu, Edginton, Laizure, Parker (bib31) 2014; 53 Fukami, Nakajima, Maruichi, Takahashi, Takamiya, Aoki, McLeod, Yokoi (bib19) 2008; 18 Paré, Eriksson, Lehr, Connolly, Eikelboom, Ezekowitz, Axelsson, Haertter, Oldgren, Reilly (bib51) 2013; 127 Hosokawa, Furihata, Yaginuma, Yamamoto, Watanabe, Tsukada, Ohhata, Kobayashi, Satoh, Chiba (bib30) 2008; 23 Ando, Saka, Ando, Sawa, Muro, Ueoka, Yokoyama, Saitoh, Shimokata, Hasegawa (bib1) 2000; 60 Heal, Pierce (bib28) 2006; 20 Zhu, Appel, Johnson, Chavin, Markowitz (bib102) 2009; 77 Yamada, Richardson, Tang, Halaschek-Wiener, Cook, Fitzgerald, Elwood, Marra, Brooks-Wilson (bib95) 2010; 10 Tarkiainen, Backman, Neuvonen, Neuvonen, Schwab, Niemi (bib81) 2012; 92 Zou, Chen, Fan, Tan, He, Xie (bib110) 2014; 63 Shi, Wang, Nguyen, Bleske, Liang, Liu, Zhu (bib70) 2016; 119 Nemoda, Angyal, Tarnok, Gadoros, Sasvari-Szekely (bib48) 2009; 57 Wiviott, Braunwald, McCabe, Montalescot, Ruzyllo, Gottlieb, Neumann, Ardissino, De Servi, Murphy (bib90) 2007; 357 Xiao, Luo, Liu, Chen, Cao, Liu, Zhou, Zhou, Zhang (bib92) 2017; 7 Williams, Carlson, Lai, Wong, Yoshimura, Critchley, Narurkar (bib89) 2011; 5 Shi, Yang, Yang, LeCluyse, Black, You, Akhlaghi, Yan (bib67) 2006; 319 Tanimoto, Kaneyasu, Shimokuni, Hiyama, Nishiyama (bib80) 2007; 17 Boberg, Vrana, Mehrotra, Pearce, Gaedigk, Bhatt, Leeder, Prasad (bib5) 2017; 45 Patrick, Straughn, Reeves, Bernstein, Bell, Anderson, Malcolm (bib54) 2013; 41 Shi, Wang, Nguyen, Wu, Bleske, Zhu (bib71) 2016; 44 Stage, Jürgens, Guski, Thomsen, Bjerre, Ferrero-Miliani, Lyauk, Rasmussen, Dalhoff (bib75) 2017; 121 Qian, Wang, Markowitz (bib55) 2019; 47 Zhu, Markowitz (bib105) 2009; 37 Yang, Pearce, Wang, Gaedigk, Wan, Yan (bib97) 2009; 77 Yancy, Jessup, Bozkurt, Butler, Casey, Colvin, Drazner, Filippatos, Fonarow, Givertz (bib96) 2017; 136 Friedrichsen, Poulsen, Wojtaszewski, Hansen, Vaag, Rasmussen (bib18) 2013; 8 Xu, Yin, Xu, Li, Zalzala, Cheng, Zhang (bib94) 2014; 9 Fukami, Yokoi (bib20) 2012; 27 Laizure, Herring, Hu, Witbrodt, Parker (bib40) 2013; 33 Wang, Wang, Shi, Aa, Comas, Liang, Zhu (bib88) 2016; 16 Arena de Souza, Scott, Nettleship, Rahman, Charlton, Walsh, Owens (bib2) 2015; 10 Johnson, Barry, Lambert, Fitzgerald, McNicholas, Kirley, Gill, Bellgrove, Hawi (bib36) 2013; 23 Xiao, Chen, Yang, Yan (bib91) 2012; 84 Foti, Dalvie (bib16) 2016; 44 Zhao, Song, St Clair, Ghosh (bib99) 2007; 292 Mahmoudpour, Asselbergs, de Keyser, Souverein, Hofman, Stricker, de Boer, Maitland-van der Zee (bib45) 2015; 37 Sai, Saito, Tatewaki, Hosokawa, Kaniwa, Nishimaki-Mogami, Naito, Sawada, Shirao, Hamaguchi (bib61) 2010; 70 Rautio, Kumpulainen, Heimbach, Oliyai, Oh, Järvinen, Savolainen (bib57) 2008; 7 Innocenti, Undevia, Iyer, Chen, Das, Kocherginsky, Karrison, Janisch, Ramírez, Rudin (bib33) 2004; 22 Zhao, Li, Sun, Mei, Ma, Miao, Zhao, Peng (bib100) 2016; 72 Ghosh, Zhao, Bie, Song (bib22) 2010; 52 Stage (10.1124/dmd.119.089680_bib74) 2017; 83 Hasin (10.1124/dmd.119.089680_bib26) 2018; 43 Sai (10.1124/dmd.119.089680_bib61) 2010; 70 Dahlgren (10.1124/dmd.119.089680_bib13) 2018; 12 Jewell (10.1124/dmd.119.089680_bib34) 2007; 74 Nemoda (10.1124/dmd.119.089680_bib48) 2009; 57 Nelveg-Kristensen (10.1124/dmd.119.089680_bib47) 2016; 26 Paré (10.1124/dmd.119.089680_bib51) 2013; 127 Wang (10.1124/dmd.119.089680_bib87) 2017; 45 Hosokawa (10.1124/dmd.119.089680_bib30) 2008; 23 Hamzic (10.1124/dmd.119.089680_bib25) 2017; 102 Suzaki (10.1124/dmd.119.089680_bib79) 2013; 69 Johnson (10.1124/dmd.119.089680_bib36) 2013; 23 Rautio (10.1124/dmd.119.089680_bib57) 2008; 7 Wang (10.1124/dmd.119.089680_bib88) 2016; 16 Scott (10.1124/dmd.119.089680_bib64) 2013; 94 He (10.1124/dmd.119.089680_bib27) 2019; 200 Zhao (10.1124/dmd.119.089680_bib100) 2016; 72 10.1124/dmd.119.089680_bib10 Crow (10.1124/dmd.119.089680_bib12) 2010; 1801 Heal (10.1124/dmd.119.089680_bib28) 2006; 20 Friedrichsen (10.1124/dmd.119.089680_bib18) 2013; 8 Yancy (10.1124/dmd.119.089680_bib96) 2017; 136 Tanimoto (10.1124/dmd.119.089680_bib80) 2007; 17 Wallentin (10.1124/dmd.119.089680_bib85) 2009; 361 Shi (10.1124/dmd.119.089680_bib68) 2008; 254 Laizure (10.1124/dmd.119.089680_bib40) 2013; 33 Ross (10.1124/dmd.119.089680_bib60) 2010; 35 Tarkiainen (10.1124/dmd.119.089680_bib82) 2015; 97 Tarkiainen (10.1124/dmd.119.089680_bib83) 2015; 80 Zou (10.1124/dmd.119.089680_bib110) 2014; 63 Xie (10.1124/dmd.119.089680_bib93) 2014; 24 Xiao (10.1124/dmd.119.089680_bib92) 2017; 7 Rhoades (10.1124/dmd.119.089680_bib58) 2012; 29 Bell (10.1124/dmd.119.089680_bib3) 2011; 100 Lian (10.1124/dmd.119.089680_bib44) 2018; 9 Parker (10.1124/dmd.119.089680_bib52) 2015; 54 Foye (10.1124/dmd.119.089680_bib17) 2013 Zhao (10.1124/dmd.119.089680_bib99) 2007; 292 Bruxel (10.1124/dmd.119.089680_bib8) 2013; 13 Imai (10.1124/dmd.119.089680_bib32) 2006; 34 Xu (10.1124/dmd.119.089680_bib94) 2014; 9 Oh (10.1124/dmd.119.089680_bib49) 2017; 12 Shi (10.1124/dmd.119.089680_bib66) 2011; 203 Shi (10.1124/dmd.119.089680_bib71) 2016; 44 Shi (10.1124/dmd.119.089680_bib69) 2016; 119 Foti (10.1124/dmd.119.089680_bib16) 2016; 44 Yang (10.1124/dmd.119.089680_bib97) 2009; 77 Fukami (10.1124/dmd.119.089680_bib19) 2008; 18 Boberg (10.1124/dmd.119.089680_bib5) 2017; 45 Singh (10.1124/dmd.119.089680_bib73) 2003; 23 Stage (10.1124/dmd.119.089680_bib75) 2017; 121 Patrick (10.1124/dmd.119.089680_bib54) 2013; 41 Zhu (10.1124/dmd.119.089680_bib108) 2008; 82 Ohtsuki (10.1124/dmd.119.089680_bib50) 2012; 40 Hu (10.1124/dmd.119.089680_bib31) 2014; 53 Lian (10.1124/dmd.119.089680_bib43) 2018; 1863 Zhu (10.1124/dmd.119.089680_bib105) 2009; 37 Cressman (10.1124/dmd.119.089680_bib11) 2015; 80 Geshi (10.1124/dmd.119.089680_bib21) 2005; 28 Roe (10.1124/dmd.119.089680_bib59) 2012; 367 Wang (10.1124/dmd.119.089680_bib86) 2016; 30 Kristensen (10.1124/dmd.119.089680_bib39) 2014; 96 Laizure (10.1124/dmd.119.089680_bib41) 2014; 42 Wiviott (10.1124/dmd.119.089680_bib90) 2007; 357 Thomsen (10.1124/dmd.119.089680_bib84) 2014; 42 Zhu (10.1124/dmd.119.089680_bib106) 2011; 879 Dolinsky (10.1124/dmd.119.089680_bib15) 2004; 61 Zhu (10.1124/dmd.119.089680_bib101) 2009; 37 Ando (10.1124/dmd.119.089680_bib1) 2000; 60 Bell (10.1124/dmd.119.089680_bib4) 2011; 100 Williams (10.1124/dmd.119.089680_bib89) 2011; 5 Shmyr (10.1124/dmd.119.089680_bib72) 2017; 63 Yamada (10.1124/dmd.119.089680_bib95) 2010; 10 Rautio (10.1124/dmd.119.089680_bib56) 2017; 109 Qian (10.1124/dmd.119.089680_bib55) 2019; 47 Shi (10.1124/dmd.119.089680_bib67) 2006; 319 Kaddurah-Daouk (10.1124/dmd.119.089680_bib38) 2018; 7 Griffin (10.1124/dmd.119.089680_bib23) 2013; 225 Patrick (10.1124/dmd.119.089680_bib53) 2007; 81 DiPiro (10.1124/dmd.119.089680_bib14) 2017 Innocenti (10.1124/dmd.119.089680_bib33) 2004; 22 Bozzi (10.1124/dmd.119.089680_bib6) 2016; 14 Hines (10.1124/dmd.119.089680_bib29) 2016; 44 Shi (10.1124/dmd.119.089680_bib70) 2016; 119 Zhu (10.1124/dmd.119.089680_bib109) 2013; 344 Jones (10.1124/dmd.119.089680_bib37) 2013; 41 Xiao (10.1124/dmd.119.089680_bib91) 2012; 84 Steinhubl (10.1124/dmd.119.089680_bib77) 2002; 288 Zhu (10.1124/dmd.119.089680_bib102) 2009; 77 Yoshimura (10.1124/dmd.119.089680_bib98) 2008; 369 Griffin (10.1124/dmd.119.089680_bib24) 2010; 95 Mehta (10.1124/dmd.119.089680_bib46) 2001; 358 Arena de Souza (10.1124/dmd.119.089680_bib2) 2015; 10 Fukami (10.1124/dmd.119.089680_bib20) 2012; 27 Tarkiainen (10.1124/dmd.119.089680_bib81) 2012; 92 Satoh (10.1124/dmd.119.089680_bib62) 2006; 162 Ghosh (10.1124/dmd.119.089680_bib22) 2010; 52 Chaturvedi (10.1124/dmd.119.089680_bib9) 2004; 17 Staudinger (10.1124/dmd.119.089680_bib76) 2010; 6 Zhu (10.1124/dmd.119.089680_bib103) 2010; 270 Zhu (10.1124/dmd.119.089680_bib104) 2016; 72 Mahmoudpour (10.1124/dmd.119.089680_bib45) 2015; 37 Lewis (10.1124/dmd.119.089680_bib42) 2013; 23 Suzaki (10.1124/dmd.119.089680_bib78) 2013; 69 Shah (10.1124/dmd.119.089680_bib65) 2014; 16 Schubert (10.1124/dmd.119.089680_bib63) 2010; 107 Zhu (10.1124/dmd.119.089680_bib107) 2017; 37 Briand (10.1124/dmd.119.089680_bib7) 2019; 24 Jiang (10.1124/dmd.119.089680_bib35) 2016; 82 33106252 - Drug Metab Dispos. 2020 Nov;48(11):1246. doi: 10.1124/dmd.119.089680err. |
| References_xml | – volume: 119 start-page: 76 year: 2016 end-page: 84 ident: bib70 article-title: Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender publication-title: Biochem Pharmacol – volume: 29 start-page: 972 year: 2012 end-page: 982 ident: bib58 article-title: Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions publication-title: Pharm Res – volume: 17 start-page: 1 year: 2007 end-page: 10 ident: bib80 article-title: Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro publication-title: Pharmacogenet Genomics – volume: 7 start-page: 255 year: 2008 end-page: 270 ident: bib57 article-title: Prodrugs: design and clinical applications publication-title: Nat Rev Drug Discov – volume: 319 start-page: 1477 year: 2006 end-page: 1484 ident: bib67 article-title: Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel publication-title: J Pharmacol Exp Ther – volume: 40 start-page: 83 year: 2012 end-page: 92 ident: bib50 article-title: Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities publication-title: Drug Metab Dispos – volume: 44 start-page: 959 year: 2016 end-page: 966 ident: bib29 article-title: Age-dependent human hepatic carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) postnatal ontogeny publication-title: Drug Metab Dispos – volume: 97 start-page: 650 year: 2015 end-page: 658 ident: bib82 article-title: Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans publication-title: Clin Pharmacol Ther – volume: 80 start-page: 1131 year: 2015 end-page: 1138 ident: bib83 article-title: Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril publication-title: Br J Clin Pharmacol – volume: 22 start-page: 1382 year: 2004 end-page: 1388 ident: bib33 article-title: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan publication-title: J Clin Oncol – volume: 77 start-page: 1266 year: 2009 end-page: 1272 ident: bib102 article-title: Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril publication-title: Biochem Pharmacol – volume: 57 start-page: 731 year: 2009 end-page: 733 ident: bib48 article-title: Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD publication-title: Neuropharmacology – volume: 102 start-page: 796 year: 2017 end-page: 804 ident: bib25 article-title: Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity publication-title: Clin Pharmacol Ther – volume: 361 start-page: 1045 year: 2009 end-page: 1057 ident: bib85 article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med – volume: 81 start-page: 346 year: 2007 end-page: 353 ident: bib53 article-title: Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics publication-title: Clin Pharmacol Ther – volume: 92 start-page: 68 year: 2012 end-page: 71 ident: bib81 article-title: Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans publication-title: Clin Pharmacol Ther – volume: 96 start-page: 713 year: 2014 end-page: 722 ident: bib39 article-title: Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study publication-title: Clin Pharmacol Ther – volume: 6 start-page: 261 year: 2010 end-page: 271 ident: bib76 article-title: Nuclear receptor-mediated regulation of carboxylesterase expression and activity publication-title: Expert Opin Drug Metab Toxicol – volume: 37 start-page: 419 year: 2017 end-page: 428 ident: bib107 article-title: Ethanol interactions with dexmethylphenidate and dl-methylphenidate spheroidal oral drug absorption systems in healthy volunteers publication-title: J Clin Psychopharmacol – volume: 270 start-page: 59 year: 2010 end-page: 65 ident: bib103 article-title: Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions publication-title: Toxicology – volume: 8 start-page: e56861 year: 2013 ident: bib18 article-title: Carboxylesterase 1 gene duplication and mRNA expression in adipose tissue are linked to obesity and metabolic function publication-title: PLoS One – volume: 5 start-page: 280 year: 2011 end-page: 289 ident: bib89 article-title: Investigation of the metabolism of rufinamide and its interaction with valproate publication-title: Drug Metab Lett – volume: 42 start-page: 126 year: 2014 end-page: 133 ident: bib84 article-title: In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors publication-title: Drug Metab Dispos – volume: 9 start-page: 178 year: 2018 end-page: 195 ident: bib44 article-title: Carboxylesterases in lipid metabolism: from mouse to human publication-title: Protein Cell – volume: 54 start-page: 627 year: 2015 end-page: 638 ident: bib52 article-title: Effects of alcohol on human carboxylesterase drug metabolism publication-title: Clin Pharmacokinet – volume: 288 start-page: 2411 year: 2002 end-page: 2420 ident: bib77 article-title: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in publication-title: JAMA – volume: 95 start-page: 267 year: 2010 end-page: 272 ident: bib24 article-title: The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice publication-title: Pharmacol Biochem Behav – volume: 16 start-page: 220 year: 2016 end-page: 230 ident: bib88 article-title: CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors publication-title: Pharmacogenomics J – volume: 292 start-page: C405 year: 2007 end-page: C412 ident: bib99 article-title: Stable overexpression of human macrophage cholesteryl ester hydrolase results in enhanced free cholesterol efflux from human THP1 macrophages publication-title: Am J Physiol Cell Physiol – volume: 83 start-page: 1506 year: 2017 end-page: 1514 ident: bib74 article-title: The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects publication-title: Br J Clin Pharmacol – volume: 879 start-page: 783 year: 2011 end-page: 788 ident: bib106 article-title: Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 82 start-page: 1241 year: 2008 end-page: 1248 ident: bib108 article-title: Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis publication-title: Am J Hum Genet – volume: 23 start-page: 73 year: 2008 end-page: 84 ident: bib30 article-title: Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes publication-title: Drug Metab Pharmacokinet – volume: 127 start-page: 1404 year: 2013 end-page: 1412 ident: bib51 article-title: Genetic determinants of dabigatran plasma levels and their relation to bleeding publication-title: Circulation – volume: 9 start-page: e109663 year: 2014 ident: bib94 article-title: Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels publication-title: PLoS One – volume: 37 start-page: 1819 year: 2009 end-page: 1825 ident: bib101 article-title: Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver publication-title: Drug Metab Dispos – volume: 23 start-page: 655 year: 2013 end-page: 664 ident: bib36 article-title: Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene publication-title: J Child Adolesc Psychopharmacol – volume: 119 start-page: 555 year: 2016 end-page: 561 ident: bib69 article-title: Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms publication-title: Basic Clin Pharmacol Toxicol – volume: 34 start-page: 1734 year: 2006 end-page: 1741 ident: bib32 article-title: Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine publication-title: Drug Metab Dispos – volume: 1863 start-page: 688 year: 2018 end-page: 699 ident: bib43 article-title: Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis publication-title: Biochim Biophys Acta Mol Cell Biol Lipids – volume: 100 start-page: 264 year: 2011 end-page: 270 ident: bib3 article-title: Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery publication-title: Pharmacol Biochem Behav – volume: 41 start-page: 40 year: 2013 end-page: 49 ident: bib37 article-title: Carboxylesterases are uniquely expressed among tissues and regulated by nuclear hormone receptors in the mouse publication-title: Drug Metab Dispos – volume: 82 start-page: 64 year: 2016 end-page: 78 ident: bib35 article-title: Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults publication-title: Eur J Pharm Sci – volume: 74 start-page: 932 year: 2007 end-page: 939 ident: bib34 article-title: Inter-individual variability in esterases in human liver publication-title: Biochem Pharmacol – volume: 7 start-page: 525 year: 2018 end-page: 533 ident: bib38 article-title: Pharmacometabolomics informs about pharmacokinetic profile of methylphenidate publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 10 start-page: e0143919 year: 2015 ident: bib2 article-title: Comparison of the structure and activity of glycosylated and aglycosylated human carboxylesterase 1 publication-title: PLoS One – volume: 72 start-page: 1195 year: 2016 end-page: 1204 ident: bib100 article-title: Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis publication-title: Eur J Clin Pharmacol – volume: 13 start-page: 476 year: 2013 end-page: 480 ident: bib8 article-title: Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate publication-title: Pharmacogenomics J – volume: 84 start-page: 232 year: 2012 end-page: 239 ident: bib91 article-title: Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation publication-title: Biochem Pharmacol – volume: 42 start-page: 201 year: 2014 end-page: 206 ident: bib41 article-title: Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis publication-title: Drug Metab Dispos – volume: 26 start-page: 169 year: 2016 end-page: 177 ident: bib47 article-title: Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors publication-title: Pharmacogenet Genomics – volume: 45 start-page: 216 year: 2017 end-page: 223 ident: bib5 article-title: Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants publication-title: Drug Metab Dispos – volume: 63 start-page: 178 year: 2014 end-page: 183 ident: bib110 article-title: CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention publication-title: J Cardiovasc Pharmacol – volume: 45 start-page: 1149 year: 2017 end-page: 1155 ident: bib87 article-title: A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms publication-title: Drug Metab Dispos – volume: 357 start-page: 2001 year: 2007 end-page: 2015 ident: bib90 article-title: Prasugrel versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med – volume: 94 start-page: 317 year: 2013 end-page: 323 ident: bib64 article-title: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update publication-title: Clin Pharmacol Ther – volume: 44 start-page: 1229 year: 2016 end-page: 1245 ident: bib16 article-title: Cytochrome P450 and non-cytochrome P450 oxidative metabolism: contributions to the pharmacokinetics, safety, and efficacy of xenobiotics publication-title: Drug Metab Dispos – volume: 72 start-page: 681 year: 2016 end-page: 687 ident: bib104 article-title: CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril publication-title: Eur J Clin Pharmacol – volume: 1801 start-page: 31 year: 2010 end-page: 41 ident: bib12 article-title: Inhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids publication-title: Biochim Biophys Acta – volume: 77 start-page: 238 year: 2009 end-page: 247 ident: bib97 article-title: Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin publication-title: Biochem Pharmacol – volume: 30 start-page: 553 year: 2016 end-page: 561 ident: bib86 article-title: Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI) publication-title: Rapid Commun Mass Spectrom – volume: 24 start-page: 2747 year: 2019 ident: bib7 article-title: Combined ensemble docking and machine learning in identification of therapeutic agents with potential inhibitory effect on human CES1 publication-title: Molecules – volume: 254 start-page: 97 year: 2008 end-page: 105 ident: bib68 article-title: Dexamethasone suppresses the expression of multiple rat carboxylesterases through transcriptional repression: evidence for an involvement of the glucocorticoid receptor publication-title: Toxicology – year: 2017 ident: bib14 publication-title: Pharmacotherapy: A Pathophysiologic Approach – volume: 52 start-page: 1 year: 2010 end-page: 10 ident: bib22 article-title: Macrophage cholesteryl ester mobilization and atherosclerosis publication-title: Vascul Pharmacol – volume: 100 start-page: 2966 year: 2011 end-page: 2978 ident: bib4 article-title: Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations publication-title: J Pharm Sci – volume: 12 start-page: e0176320 year: 2017 ident: bib49 article-title: The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans publication-title: PLoS One – volume: 69 start-page: 735 year: 2013 end-page: 736 ident: bib78 article-title: Gly143Glu polymorphism of the human carboxylesterase1 gene in an Asian population publication-title: Eur J Clin Pharmacol – volume: 344 start-page: 665 year: 2013 end-page: 672 ident: bib109 article-title: Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation publication-title: J Pharmacol Exp Ther – volume: 18 start-page: 911 year: 2008 end-page: 920 ident: bib19 article-title: Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes publication-title: Pharmacogenet Genomics – volume: 41 start-page: 197 year: 2013 end-page: 205 ident: bib54 article-title: Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans publication-title: Drug Metab Dispos – volume: 14 start-page: 116 year: 2016 end-page: 124 ident: bib6 article-title: The pharmacogenomics of anti-platelet intervention (PAPI) study: variation in platelet response to clopidogrel and aspirin publication-title: Curr Vasc Pharmacol – volume: 20 start-page: 713 year: 2006 end-page: 738 ident: bib28 article-title: Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system publication-title: CNS Drugs – volume: 80 start-page: 662 year: 2015 end-page: 669 ident: bib11 article-title: A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors publication-title: Br J Clin Pharmacol – volume: 367 start-page: 1297 year: 2012 end-page: 1309 ident: bib59 article-title: Prasugrel versus clopidogrel for acute coronary syndromes without revascularization publication-title: N Engl J Med – volume: 107 start-page: 615 year: 2010 end-page: 621 ident: bib63 article-title: The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007 publication-title: Dtsch Arztebl Int – volume: 69 start-page: 21 year: 2013 end-page: 30 ident: bib79 article-title: The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans publication-title: Eur J Clin Pharmacol – volume: 200 start-page: 51 year: 2019 end-page: 59 ident: bib27 article-title: Label-free absolute protein quantification with data-independent acquisition publication-title: J Proteomics – volume: 162 start-page: 195 year: 2006 end-page: 211 ident: bib62 article-title: Structure, function and regulation of carboxylesterases publication-title: Chem Biol Interact – volume: 12 start-page: 465 year: 2018 end-page: 474 ident: bib13 article-title: Evaluating oseltamivir prescriptions in Centers for Medicare and Medicaid Services medical claims records as an indicator of seasonal influenza in the United States publication-title: Influenza Other Respir Viruses – volume: 37 start-page: 1095 year: 2015 end-page: 1103 ident: bib45 article-title: Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors publication-title: Int J Clin Pharm – volume: 23 start-page: 561 year: 2003 end-page: 569 ident: bib73 article-title: Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis publication-title: Clin Drug Investig – volume: 47 start-page: 465 year: 2019 end-page: 472 ident: bib55 article-title: In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites publication-title: Drug Metab Dispos – volume: 28 start-page: 719 year: 2005 end-page: 725 ident: bib21 article-title: A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity publication-title: Hypertens Res – volume: 24 start-page: 204 year: 2014 end-page: 210 ident: bib93 article-title: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease publication-title: Pharmacogenet Genomics – volume: 43 start-page: 195 year: 2018 end-page: 212 ident: bib26 article-title: US epidemiology of cannabis use and associated problems publication-title: Neuropsychopharmacology – volume: 44 start-page: 554 year: 2016 end-page: 559 ident: bib71 article-title: Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation publication-title: Drug Metab Dispos – volume: 10 start-page: 524 year: 2010 end-page: 536 ident: bib95 article-title: Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity publication-title: Pharmacogenomics J – volume: 109 start-page: 146 year: 2017 end-page: 161 ident: bib56 article-title: Prodrugs - recent approvals and a glimpse of the pipeline publication-title: Eur J Pharm Sci – volume: 369 start-page: 939 year: 2008 end-page: 942 ident: bib98 article-title: Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites publication-title: Biochem Biophys Res Commun – volume: 7 start-page: 1 year: 2017 end-page: 6 ident: bib92 article-title: Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients publication-title: Sci Rep – volume: 33 start-page: 210 year: 2013 end-page: 222 ident: bib40 article-title: The role of human carboxylesterases in drug metabolism: have we overlooked their importance? publication-title: Pharmacotherapy – year: 2013 ident: bib17 publication-title: Foye’s Principles of Medicinal Chemistry – volume: 23 start-page: 1 year: 2013 end-page: 8 ident: bib42 article-title: The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response publication-title: Pharmacogenet Genomics – volume: 225 start-page: 613 year: 2013 end-page: 625 ident: bib23 article-title: Interactive effects of methylphenidate and alcohol on discrimination, conditioned place preference and motor coordination in C57BL/6J mice publication-title: Psychopharmacology (Berl) – volume: 37 start-page: 264 year: 2009 end-page: 267 ident: bib105 article-title: Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants publication-title: Drug Metab Dispos – volume: 16 start-page: 894 year: 2014 end-page: 898 ident: bib65 article-title: G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS publication-title: AAPS J – volume: 53 start-page: 825 year: 2014 end-page: 836 ident: bib31 article-title: Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition [published correction appears in publication-title: Clin Pharmacokinet – volume: 203 start-page: 937 year: 2011 end-page: 942 ident: bib66 article-title: Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir publication-title: J Infect Dis – volume: 17 start-page: 227 year: 2004 ident: bib9 article-title: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): is it really practical? publication-title: Natl Med J India – volume: 60 start-page: 6921 year: 2000 end-page: 6926 ident: bib1 article-title: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis publication-title: Cancer Res – volume: 358 start-page: 527 year: 2001 end-page: 533 ident: bib46 article-title: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study publication-title: Lancet – volume: 121 start-page: 487 year: 2017 end-page: 492 ident: bib75 article-title: The pharmacokinetics of enalapril in relation to CES1 genotype in healthy Danish volunteers publication-title: Basic Clin Pharmacol Toxicol – volume: 70 start-page: 222 year: 2010 end-page: 233 ident: bib61 article-title: Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients publication-title: Br J Clin Pharmacol – volume: 27 start-page: 466 year: 2012 end-page: 477 ident: bib20 article-title: The emerging role of human esterases publication-title: Drug Metab Pharmacokinet – volume: 63 start-page: 375 year: 2017 end-page: 381 ident: bib72 article-title: Triple antithrombotic therapy for atrial fibrillation and coronary stents publication-title: Can Fam Physician – volume: 35 start-page: 257 year: 2010 end-page: 264 ident: bib60 article-title: Carboxylesterases: dual roles in lipid and pesticide metabolism publication-title: J Pestic Sci – reference: COTEMPLA XR-ODT(TM) (2017) Product Information: COTEMPLA XR-ODT(TM) oral extended-release disintegrating tablets, methylphenidate oral extended-release disintegrating tablets. Neos Therapeutics IGP, Grand Prairie, TX. – volume: 136 start-page: e137 year: 2017 end-page: e161 ident: bib96 article-title: 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America publication-title: Circulation – volume: 61 start-page: 1633 year: 2004 end-page: 1651 ident: bib15 article-title: Triacylglycerol hydrolase: role in intracellular lipid metabolism publication-title: Cell Mol Life Sci – year: 2017 ident: 10.1124/dmd.119.089680_bib14 – volume: 42 start-page: 201 year: 2014 ident: 10.1124/dmd.119.089680_bib41 article-title: Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis publication-title: Drug Metab Dispos doi: 10.1124/dmd.113.054353 – volume: 70 start-page: 222 year: 2010 ident: 10.1124/dmd.119.089680_bib61 article-title: Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2010.03695.x – volume: 162 start-page: 195 year: 2006 ident: 10.1124/dmd.119.089680_bib62 article-title: Structure, function and regulation of carboxylesterases publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2006.07.001 – volume: 1863 start-page: 688 year: 2018 ident: 10.1124/dmd.119.089680_bib43 article-title: Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis publication-title: Biochim Biophys Acta Mol Cell Biol Lipids doi: 10.1016/j.bbalip.2018.04.002 – volume: 1801 start-page: 31 year: 2010 ident: 10.1124/dmd.119.089680_bib12 article-title: Inhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids publication-title: Biochim Biophys Acta doi: 10.1016/j.bbalip.2009.09.002 – volume: 22 start-page: 1382 year: 2004 ident: 10.1124/dmd.119.089680_bib33 article-title: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan publication-title: J Clin Oncol doi: 10.1200/JCO.2004.07.173 – volume: 45 start-page: 1149 year: 2017 ident: 10.1124/dmd.119.089680_bib87 article-title: A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms publication-title: Drug Metab Dispos doi: 10.1124/dmd.117.077669 – volume: 7 start-page: 255 year: 2008 ident: 10.1124/dmd.119.089680_bib57 article-title: Prodrugs: design and clinical applications publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2468 – volume: 72 start-page: 681 year: 2016 ident: 10.1124/dmd.119.089680_bib104 article-title: CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-016-2029-x – volume: 14 start-page: 116 year: 2016 ident: 10.1124/dmd.119.089680_bib6 article-title: The pharmacogenomics of anti-platelet intervention (PAPI) study: variation in platelet response to clopidogrel and aspirin publication-title: Curr Vasc Pharmacol doi: 10.2174/1570161113666150916094829 – volume: 97 start-page: 650 year: 2015 ident: 10.1124/dmd.119.089680_bib82 article-title: Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.101 – volume: 34 start-page: 1734 year: 2006 ident: 10.1124/dmd.119.089680_bib32 article-title: Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine publication-title: Drug Metab Dispos doi: 10.1124/dmd.106.009381 – volume: 44 start-page: 554 year: 2016 ident: 10.1124/dmd.119.089680_bib71 article-title: Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.068536 – volume: 29 start-page: 972 year: 2012 ident: 10.1124/dmd.119.089680_bib58 article-title: Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions publication-title: Pharm Res doi: 10.1007/s11095-011-0637-9 – volume: 23 start-page: 655 year: 2013 ident: 10.1124/dmd.119.089680_bib36 article-title: Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene publication-title: J Child Adolesc Psychopharmacol doi: 10.1089/cap.2013.0032 – volume: 69 start-page: 21 year: 2013 ident: 10.1124/dmd.119.089680_bib79 article-title: The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-012-1315-5 – volume: 45 start-page: 216 year: 2017 ident: 10.1124/dmd.119.089680_bib5 article-title: Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants publication-title: Drug Metab Dispos doi: 10.1124/dmd.116.072652 – ident: 10.1124/dmd.119.089680_bib10 – volume: 225 start-page: 613 year: 2013 ident: 10.1124/dmd.119.089680_bib23 article-title: Interactive effects of methylphenidate and alcohol on discrimination, conditioned place preference and motor coordination in C57BL/6J mice publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-012-2849-z – volume: 16 start-page: 894 year: 2014 ident: 10.1124/dmd.119.089680_bib65 article-title: G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS publication-title: AAPS J doi: 10.1208/s12248-014-9620-9 – volume: 35 start-page: 257 year: 2010 ident: 10.1124/dmd.119.089680_bib60 article-title: Carboxylesterases: dual roles in lipid and pesticide metabolism publication-title: J Pestic Sci doi: 10.1584/jpestics.R10-07 – volume: 37 start-page: 419 year: 2017 ident: 10.1124/dmd.119.089680_bib107 article-title: Ethanol interactions with dexmethylphenidate and dl-methylphenidate spheroidal oral drug absorption systems in healthy volunteers publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0000000000000721 – volume: 344 start-page: 665 year: 2013 ident: 10.1124/dmd.119.089680_bib109 article-title: Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.112.201640 – volume: 52 start-page: 1 year: 2010 ident: 10.1124/dmd.119.089680_bib22 article-title: Macrophage cholesteryl ester mobilization and atherosclerosis publication-title: Vascul Pharmacol doi: 10.1016/j.vph.2009.10.002 – volume: 9 start-page: 178 year: 2018 ident: 10.1124/dmd.119.089680_bib44 article-title: Carboxylesterases in lipid metabolism: from mouse to human publication-title: Protein Cell doi: 10.1007/s13238-017-0437-z – volume: 361 start-page: 1045 year: 2009 ident: 10.1124/dmd.119.089680_bib85 article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med doi: 10.1056/NEJMoa0904327 – volume: 16 start-page: 220 year: 2016 ident: 10.1124/dmd.119.089680_bib88 article-title: CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors publication-title: Pharmacogenomics J doi: 10.1038/tpj.2015.42 – volume: 23 start-page: 561 year: 2003 ident: 10.1124/dmd.119.089680_bib73 article-title: Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis publication-title: Clin Drug Investig doi: 10.2165/00044011-200323090-00002 – volume: 102 start-page: 796 year: 2017 ident: 10.1124/dmd.119.089680_bib25 article-title: Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.641 – volume: 100 start-page: 2966 year: 2011 ident: 10.1124/dmd.119.089680_bib4 article-title: Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations publication-title: J Pharm Sci doi: 10.1002/jps.22476 – volume: 81 start-page: 346 year: 2007 ident: 10.1124/dmd.119.089680_bib53 article-title: Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100082 – volume: 82 start-page: 1241 year: 2008 ident: 10.1124/dmd.119.089680_bib108 article-title: Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2008.04.015 – volume: 10 start-page: 524 year: 2010 ident: 10.1124/dmd.119.089680_bib95 article-title: Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity publication-title: Pharmacogenomics J doi: 10.1038/tpj.2010.5 – volume: 17 start-page: 227 year: 2004 ident: 10.1124/dmd.119.089680_bib9 article-title: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): is it really practical? publication-title: Natl Med J India – volume: 24 start-page: 2747 year: 2019 ident: 10.1124/dmd.119.089680_bib7 article-title: Combined ensemble docking and machine learning in identification of therapeutic agents with potential inhibitory effect on human CES1 publication-title: Molecules doi: 10.3390/molecules24152747 – volume: 82 start-page: 64 year: 2016 ident: 10.1124/dmd.119.089680_bib35 article-title: Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2015.10.024 – volume: 10 start-page: e0143919 year: 2015 ident: 10.1124/dmd.119.089680_bib2 article-title: Comparison of the structure and activity of glycosylated and aglycosylated human carboxylesterase 1 publication-title: PLoS One doi: 10.1371/journal.pone.0143919 – volume: 63 start-page: 375 year: 2017 ident: 10.1124/dmd.119.089680_bib72 article-title: Triple antithrombotic therapy for atrial fibrillation and coronary stents publication-title: Can Fam Physician – volume: 17 start-page: 1 year: 2007 ident: 10.1124/dmd.119.089680_bib80 article-title: Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro publication-title: Pharmacogenet Genomics doi: 10.1097/01.fpc.0000230110.18957.50 – volume: 20 start-page: 713 year: 2006 ident: 10.1124/dmd.119.089680_bib28 article-title: Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system publication-title: CNS Drugs doi: 10.2165/00023210-200620090-00002 – volume: 77 start-page: 238 year: 2009 ident: 10.1124/dmd.119.089680_bib97 article-title: Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2008.10.005 – volume: 100 start-page: 264 year: 2011 ident: 10.1124/dmd.119.089680_bib3 article-title: Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2011.08.026 – volume: 23 start-page: 73 year: 2008 ident: 10.1124/dmd.119.089680_bib30 article-title: Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.23.73 – volume: 80 start-page: 662 year: 2015 ident: 10.1124/dmd.119.089680_bib11 article-title: A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12682 – volume: 95 start-page: 267 year: 2010 ident: 10.1124/dmd.119.089680_bib24 article-title: The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2010.01.009 – volume: 127 start-page: 1404 year: 2013 ident: 10.1124/dmd.119.089680_bib51 article-title: Genetic determinants of dabigatran plasma levels and their relation to bleeding publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.112.001233 – volume: 288 start-page: 2411 year: 2002 ident: 10.1124/dmd.119.089680_bib77 article-title: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA (2003) 289:987] publication-title: JAMA doi: 10.1001/jama.288.19.2411 – volume: 30 start-page: 553 year: 2016 ident: 10.1124/dmd.119.089680_bib86 article-title: Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled full-length protein calibrators (TAQSI) publication-title: Rapid Commun Mass Spectrom doi: 10.1002/rcm.7482 – volume: 18 start-page: 911 year: 2008 ident: 10.1124/dmd.119.089680_bib19 article-title: Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e32830b0c5e – volume: 57 start-page: 731 year: 2009 ident: 10.1124/dmd.119.089680_bib48 article-title: Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2009.08.014 – volume: 6 start-page: 261 year: 2010 ident: 10.1124/dmd.119.089680_bib76 article-title: Nuclear receptor-mediated regulation of carboxylesterase expression and activity publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425250903483215 – volume: 26 start-page: 169 year: 2016 ident: 10.1124/dmd.119.089680_bib47 article-title: Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000203 – volume: 44 start-page: 1229 year: 2016 ident: 10.1124/dmd.119.089680_bib16 article-title: Cytochrome P450 and non-cytochrome P450 oxidative metabolism: contributions to the pharmacokinetics, safety, and efficacy of xenobiotics publication-title: Drug Metab Dispos doi: 10.1124/dmd.116.071753 – volume: 96 start-page: 713 year: 2014 ident: 10.1124/dmd.119.089680_bib39 article-title: Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.183 – volume: 13 start-page: 476 year: 2013 ident: 10.1124/dmd.119.089680_bib8 article-title: Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate publication-title: Pharmacogenomics J doi: 10.1038/tpj.2012.25 – volume: 369 start-page: 939 year: 2008 ident: 10.1124/dmd.119.089680_bib98 article-title: Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.02.120 – volume: 200 start-page: 51 year: 2019 ident: 10.1124/dmd.119.089680_bib27 article-title: Label-free absolute protein quantification with data-independent acquisition publication-title: J Proteomics doi: 10.1016/j.jprot.2019.03.005 – volume: 367 start-page: 1297 year: 2012 ident: 10.1124/dmd.119.089680_bib59 article-title: Prasugrel versus clopidogrel for acute coronary syndromes without revascularization publication-title: N Engl J Med doi: 10.1056/NEJMoa1205512 – volume: 357 start-page: 2001 year: 2007 ident: 10.1124/dmd.119.089680_bib90 article-title: Prasugrel versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med doi: 10.1056/NEJMoa0706482 – volume: 77 start-page: 1266 year: 2009 ident: 10.1124/dmd.119.089680_bib102 article-title: Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2008.12.017 – volume: 12 start-page: e0176320 year: 2017 ident: 10.1124/dmd.119.089680_bib49 article-title: The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans publication-title: PLoS One doi: 10.1371/journal.pone.0176320 – volume: 44 start-page: 959 year: 2016 ident: 10.1124/dmd.119.089680_bib29 article-title: Age-dependent human hepatic carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) postnatal ontogeny publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.068957 – volume: 136 start-page: e137 year: 2017 ident: 10.1124/dmd.119.089680_bib96 publication-title: Circulation doi: 10.1161/CIR.0000000000000509 – volume: 43 start-page: 195 year: 2018 ident: 10.1124/dmd.119.089680_bib26 article-title: US epidemiology of cannabis use and associated problems publication-title: Neuropsychopharmacology doi: 10.1038/npp.2017.198 – volume: 63 start-page: 178 year: 2014 ident: 10.1124/dmd.119.089680_bib110 article-title: CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention publication-title: J Cardiovasc Pharmacol doi: 10.1097/FJC.0000000000000037 – volume: 72 start-page: 1195 year: 2016 ident: 10.1124/dmd.119.089680_bib100 article-title: Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-016-2094-1 – volume: 54 start-page: 627 year: 2015 ident: 10.1124/dmd.119.089680_bib52 article-title: Effects of alcohol on human carboxylesterase drug metabolism publication-title: Clin Pharmacokinet doi: 10.1007/s40262-014-0226-2 – volume: 7 start-page: 525 year: 2018 ident: 10.1124/dmd.119.089680_bib38 article-title: Pharmacometabolomics informs about pharmacokinetic profile of methylphenidate publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1002/psp4.12309 – volume: 121 start-page: 487 year: 2017 ident: 10.1124/dmd.119.089680_bib75 article-title: The pharmacokinetics of enalapril in relation to CES1 genotype in healthy Danish volunteers publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/bcpt.12835 – volume: 61 start-page: 1633 year: 2004 ident: 10.1124/dmd.119.089680_bib15 article-title: Triacylglycerol hydrolase: role in intracellular lipid metabolism publication-title: Cell Mol Life Sci doi: 10.1007/s00018-004-3426-3 – volume: 119 start-page: 555 year: 2016 ident: 10.1124/dmd.119.089680_bib69 article-title: Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/bcpt.12625 – volume: 80 start-page: 1131 year: 2015 ident: 10.1124/dmd.119.089680_bib83 article-title: Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12667 – volume: 84 start-page: 232 year: 2012 ident: 10.1124/dmd.119.089680_bib91 article-title: Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2012.04.002 – volume: 41 start-page: 40 year: 2013 ident: 10.1124/dmd.119.089680_bib37 article-title: Carboxylesterases are uniquely expressed among tissues and regulated by nuclear hormone receptors in the mouse publication-title: Drug Metab Dispos doi: 10.1124/dmd.112.048397 – volume: 60 start-page: 6921 year: 2000 ident: 10.1124/dmd.119.089680_bib1 article-title: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis publication-title: Cancer Res – volume: 292 start-page: C405 year: 2007 ident: 10.1124/dmd.119.089680_bib99 article-title: Stable overexpression of human macrophage cholesteryl ester hydrolase results in enhanced free cholesterol efflux from human THP1 macrophages publication-title: Am J Physiol Cell Physiol doi: 10.1152/ajpcell.00306.2006 – volume: 37 start-page: 264 year: 2009 ident: 10.1124/dmd.119.089680_bib105 article-title: Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants publication-title: Drug Metab Dispos doi: 10.1124/dmd.108.024943 – volume: 203 start-page: 937 year: 2011 ident: 10.1124/dmd.119.089680_bib66 article-title: Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir publication-title: J Infect Dis doi: 10.1093/infdis/jiq145 – volume: 69 start-page: 735 year: 2013 ident: 10.1124/dmd.119.089680_bib78 article-title: Gly143Glu polymorphism of the human carboxylesterase1 gene in an Asian population publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-012-1352-0 – year: 2013 ident: 10.1124/dmd.119.089680_bib17 – volume: 40 start-page: 83 year: 2012 ident: 10.1124/dmd.119.089680_bib50 article-title: Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities publication-title: Drug Metab Dispos doi: 10.1124/dmd.111.042259 – volume: 24 start-page: 204 year: 2014 ident: 10.1124/dmd.119.089680_bib93 article-title: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000035 – volume: 47 start-page: 465 year: 2019 ident: 10.1124/dmd.119.089680_bib55 article-title: In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites publication-title: Drug Metab Dispos doi: 10.1124/dmd.118.086074 – volume: 37 start-page: 1095 year: 2015 ident: 10.1124/dmd.119.089680_bib45 article-title: Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors publication-title: Int J Clin Pharm doi: 10.1007/s11096-015-0159-3 – volume: 12 start-page: 465 year: 2018 ident: 10.1124/dmd.119.089680_bib13 article-title: Evaluating oseltamivir prescriptions in Centers for Medicare and Medicaid Services medical claims records as an indicator of seasonal influenza in the United States publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12552 – volume: 28 start-page: 719 year: 2005 ident: 10.1124/dmd.119.089680_bib21 article-title: A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity publication-title: Hypertens Res doi: 10.1291/hypres.28.719 – volume: 42 start-page: 126 year: 2014 ident: 10.1124/dmd.119.089680_bib84 article-title: In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors publication-title: Drug Metab Dispos doi: 10.1124/dmd.113.053512 – volume: 319 start-page: 1477 year: 2006 ident: 10.1124/dmd.119.089680_bib67 article-title: Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.106.111807 – volume: 27 start-page: 466 year: 2012 ident: 10.1124/dmd.119.089680_bib20 article-title: The emerging role of human esterases publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-12-RV-042 – volume: 254 start-page: 97 year: 2008 ident: 10.1124/dmd.119.089680_bib68 article-title: Dexamethasone suppresses the expression of multiple rat carboxylesterases through transcriptional repression: evidence for an involvement of the glucocorticoid receptor publication-title: Toxicology doi: 10.1016/j.tox.2008.09.019 – volume: 41 start-page: 197 year: 2013 ident: 10.1124/dmd.119.089680_bib54 article-title: Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans publication-title: Drug Metab Dispos doi: 10.1124/dmd.112.048595 – volume: 7 start-page: 1 year: 2017 ident: 10.1124/dmd.119.089680_bib92 article-title: Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients publication-title: Sci Rep doi: 10.1038/s41598-017-07736-1 – volume: 33 start-page: 210 year: 2013 ident: 10.1124/dmd.119.089680_bib40 article-title: The role of human carboxylesterases in drug metabolism: have we overlooked their importance? publication-title: Pharmacotherapy doi: 10.1002/phar.1194 – volume: 8 start-page: e56861 year: 2013 ident: 10.1124/dmd.119.089680_bib18 article-title: Carboxylesterase 1 gene duplication and mRNA expression in adipose tissue are linked to obesity and metabolic function publication-title: PLoS One doi: 10.1371/journal.pone.0056861 – volume: 94 start-page: 317 year: 2013 ident: 10.1124/dmd.119.089680_bib64 article-title: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2013.105 – volume: 92 start-page: 68 year: 2012 ident: 10.1124/dmd.119.089680_bib81 article-title: Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.13 – volume: 879 start-page: 783 year: 2011 ident: 10.1124/dmd.119.089680_bib106 article-title: Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2011.02.033 – volume: 107 start-page: 615 year: 2010 ident: 10.1124/dmd.119.089680_bib63 article-title: The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007 publication-title: Dtsch Arztebl Int – volume: 74 start-page: 932 year: 2007 ident: 10.1124/dmd.119.089680_bib34 article-title: Inter-individual variability in esterases in human liver publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2007.06.022 – volume: 37 start-page: 1819 year: 2009 ident: 10.1124/dmd.119.089680_bib101 article-title: Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver publication-title: Drug Metab Dispos doi: 10.1124/dmd.109.028209 – volume: 23 start-page: 1 year: 2013 ident: 10.1124/dmd.119.089680_bib42 article-title: The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e32835aa8a2 – volume: 53 start-page: 825 year: 2014 ident: 10.1124/dmd.119.089680_bib31 article-title: Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition [published correction appears in Clin Pharmacokinet (2014) 53:959] publication-title: Clin Pharmacokinet doi: 10.1007/s40262-014-0160-3 – volume: 358 start-page: 527 year: 2001 ident: 10.1124/dmd.119.089680_bib46 article-title: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study publication-title: Lancet doi: 10.1016/S0140-6736(01)05701-4 – volume: 5 start-page: 280 year: 2011 ident: 10.1124/dmd.119.089680_bib89 article-title: Investigation of the metabolism of rufinamide and its interaction with valproate publication-title: Drug Metab Lett doi: 10.2174/187231211798472511 – volume: 119 start-page: 76 year: 2016 ident: 10.1124/dmd.119.089680_bib70 article-title: Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2016.09.003 – volume: 9 start-page: e109663 year: 2014 ident: 10.1124/dmd.119.089680_bib94 article-title: Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels publication-title: PLoS One doi: 10.1371/journal.pone.0109663 – volume: 109 start-page: 146 year: 2017 ident: 10.1124/dmd.119.089680_bib56 article-title: Prodrugs - recent approvals and a glimpse of the pipeline publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2017.08.002 – volume: 270 start-page: 59 year: 2010 ident: 10.1124/dmd.119.089680_bib103 article-title: Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions publication-title: Toxicology doi: 10.1016/j.tox.2010.01.009 – volume: 83 start-page: 1506 year: 2017 ident: 10.1124/dmd.119.089680_bib74 article-title: The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13237 – reference: 33106252 - Drug Metab Dispos. 2020 Nov;48(11):1246. doi: 10.1124/dmd.119.089680err. |
| SSID | ssj0014439 |
| Score | 2.5564744 |
| SecondaryResourceType | review_article |
| Snippet | Carboxylesterase (CES) 1 is the most abundant drug-metabolizing enzyme in human livers, comprising approximately 1% of the entire liver proteome. CES1 is... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 230 |
| SubjectTerms | Biomarkers Carboxylesterase Carboxylic Ester Hydrolases - genetics Chemical compounds Copy number DNA Copy Number Variations - genetics Drug therapy Drugs Humans Liver Nucleotides Pesticides Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - metabolism Pharmacodynamics Pharmacogenetics Pharmacogenetics - methods Pharmacokinetics Pharmacology Pollutants Polymorphism, Single Nucleotide Precision Medicine Prodrugs Proteomes Regulators Single-nucleotide polymorphism Substrates |
| Title | Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators |
| URI | https://dx.doi.org/10.1124/dmd.119.089680 https://www.ncbi.nlm.nih.gov/pubmed/31871135 https://www.proquest.com/docview/2375821796 https://www.proquest.com/docview/2330328595 https://pubmed.ncbi.nlm.nih.gov/PMC7031766 |
| Volume | 48 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgvPCC-KZsICOh8bBlNIkTx7yhsWmaStlDKkUIKfJXWKWSTF0jUX49N47jtN0qDV6i1HGdKOfYvtfxPReh95xTKajvQ09j0iMc-hyPCPcE9xOmgUHciPp8HcdnE3KeRVmfONFElyzEkfxza1zJ_6AKZYBrEyX7D8i6RqEAzgFfOALCcLwTxsd8Lqrfy5lRO4Dp6MC3m_9t4pyDCytM3UZZGXGnrgga1U6ieVyV9je8b5OcvrJfeazd-mVe_2yyTQNlZl1aDTV1W776FVVDgFEt3Ur998vaTG-88s6nenWRATxKt8uqGxcD3wNzLGunjVvK7GBKkhXShKsjY_v55eaIHRB4zeqXglN2NExY3GZ2WpfGHn_LTyejUZ6eZOl99CAAn8BEdmduPw84hiZtnHsqq9AJ7X9cb32bBXLTw9jcKLtieaSP0SPrMuDPLf5P0D1dPkX7FsflIU77ELrrQ7yPL3o18uUz9GOTJNjHgB52JMEbJPmENyli6vcUwT1FnqPJ6Ul6fObZlBqeBLt-4QVMU64Y1awItEqKuOCCxIKIQjMmSRSooQALN9SJSkRBKS1CKv2hVAmTlDAVvkA7ZVXqVwhrIihLilAoDi6-DgUXEsznOFGqSLTUA-R1rzmXVm--SXsyy43fGZAcYIETlrewDNAHV_-qVVrZWtPvUMutndjafzmQaut_9jp4c9uDr_MgpE2cOGXxAL1zl2F8bT6a8VJXdVMnbCQnIxYN0MuWDe7xYD6EYS6EK3SNJ65Co92-fqWcXhoN9yZtBI3j13e47y562HfJPbSzmNf6DVjCC_HW9IC_6y65yg |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Carboxylesterase+1+and+Precision+Pharmacotherapy%3A+Pharmacogenetics+and+Nongenetic+Regulators&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Her%2C+Lucy&rft.au=Zhu%2C+Hao-Jie&rft.date=2020-03-01&rft.issn=1521-009X&rft.eissn=1521-009X&rft.volume=48&rft.issue=3&rft.spage=230&rft_id=info:doi/10.1124%2Fdmd.119.089680&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon |